Top of the morning to you, and a fine one it is. Despite the oppressive heat, we are keeping a cool demeanor. And why not? There is much to keep us gainfully occupied and, on this side of the pond, we have a holiday tomorrow. This reminds us to say that we will take a break and return in two days. Meanwhile, please enjoy the tidbits we have assembled and we hope that you also get to enjoy a break. See you soon …

Public health officials are expanding efforts to get the HIV prevention pill into the hands of those at risk in a nationwide effort to curb infections, but there are barriers, Kaiser Health News reports. Officials are hitting roadblocks such as the price of the drug, which has surged in recent years, and changes in insurance coverage that put a heftier financial burden on patients. Since Truvada was approved six years ago, its average wholesale price has climbed by about 45 percent. Now, the Gilead Sciences (GILD) drug carries a list price of close to $2,000 for a 30-day supply.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy